AAIPharma & Cambridge Major Laboratories Announce New CEO
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. recently announced the appointment of Stephan Kutzer, PhD, as CEO, effective August 1, 2014.
“AAIPharma and Cambridge Major Laboratories are highly regarded for their expertise in pharmaceutical development and manufacturing services for clients around the world. These companies offer the unique set of people, capabilities, and continuum of services required to enhance and expedite pharmaceutical development globally. Stephan brings valuable leadership experience with over 18 years in the pharmaceutical industry. His diverse background in operations, technical services, API development, and manufacturing positions him well to take our company to the next level,” said Susan Nestegard, acting CEO. “He will continue our focus on best in class safety, quality, and exceeding customer expectations to achieve our vision of being the Contract Manufacturing and Development Organization (CDMO) of first choice in the pharmaceutical sector.”
Most recently, Dr. Kutzer served as Chief Operating Officer of Lonza, Inc. (part of the Lonza Group, a Swiss chemicals and biotechnology company). Since 2003, he has also served as Chief Operating Officer and/or President of several divisions, including Lonza Pharma Biotech Division, Lonza Custom Manufacturing, Lonza Biopharmaceuticals and Lonza Performance Chemicals. From 1999 to 2002, he served as Site Director and Vice President of Operations of Lonza’s Bayport, Texas facilities, and in 1999, he was Director of Process Improvement at Lonza Guangzhou Ltd. Guangzhou, PR China. At Lonza Visp, he was Production and Plant Manager (1998) and Assistant Production Manager (1996) of Nicotinates. Dr. Kutzer holds a Master’s Degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences (Chemical Engineering) from the Technical University of Munich, Germany.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With nearly 800 employees operating out of seven sites in the US and Europe, combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. For more information, visit www.aaipharma.com and www.c-mlabs.com/.
Total Page Views: 1144
